New Indications for TIPSs: What Do We Know So Far?

被引:6
|
作者
Lapenna, Lucia [1 ]
Di Cola, Simone [1 ]
Gazda, Jakub [2 ,3 ]
De Felice, Ilaria [1 ]
Gioia, Stefania [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[2] Safarik Univ, Dept Internal Med 2, Kosice, Slovakia
[3] L Pasteur Univ Hosp Kosice, Kosice, Slovakia
关键词
transjugular intrahepatic portosystemic shunt; portal hyperten-sion; surgery; portal vein thrombosis; Budd-Chiari syndrome; INTRAHEPATIC PORTOSYSTEMIC SHUNT; PORTAL-VEIN THROMBOSIS; PARACENTESIS PLUS ALBUMIN; BUDD-CHIARI-SYNDROME; CIRRHOTIC-PATIENTS; REFRACTORY ASCITES; HEPATIC-ENCEPHALOPATHY; RISK-FACTOR; NONHEPATIC SURGERY; LIVER-CIRRHOSIS;
D O I
10.1016/j.jceh.2023.01.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent results have been achieved with this therapeutic strategy. The historical indications for TIPS placement, in the context of liver cirrhosis, such as refractory ascites and variceal bleeding are now well established and known. However, in recent years, new indications are emerging. These have been investigated and approved in some studies but are not yet included in guidelines and clinical practice. This review aims to highlight what is new for the role of TIPS in portal vein thrombosis (especially in patients awaiting liver transplantation), in recurrent ascites and not only refractory ascites, as a neoadjuvant therapy before abdominal surgery and, finally, in the setting of noncirrhotic portal hypertension. All these new aspects are addressed in this review with a critical approach based on the literature revision and clinical practice. Future research is needed to explore and validate the new role of TIPS in these scenarios. ( J CLIN EXP HEPATOL 2023;13:794-803)
引用
收藏
页码:794 / 803
页数:10
相关论文
共 50 条
  • [1] Amyloidogenesis: What Do We Know So Far?
    Alraawi, Zeina
    Banerjee, Nayan
    Mohanty, Srujana
    Kumar, Thallapuranam Krishnaswamy Suresh
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [2] ASPHALTENES: WHAT DO WE KNOW SO FAR
    Al-Qasim, Abdulaziz S.
    Alasker, Mohammed
    PROCEEDINGS OF THE ASME 36TH INTERNATIONAL CONFERENCE ON OCEAN, OFFSHORE AND ARCTIC ENGINEERING, 2017, VOL 8, 2017,
  • [3] Probiotics: What Do We Know So Far?
    Steinberg, Skylar
    Hazan, Sabine
    PRACTICAL GASTROENTEROLOGY, 2018, 42 (10) : 68 - 70
  • [4] Trichotillomania: What Do We Know So Far?
    Melo, Daniel Fernandes
    Lima, Caren dos Santos
    Piraccini, Bianca Maria
    Tosti, Antonella
    SKIN APPENDAGE DISORDERS, 2022, 8 (01) : 1 - 7
  • [5] Crowdfunding: What Do We Know So Far?
    Jovanovic, Tanja
    INTERNATIONAL JOURNAL OF INNOVATION AND TECHNOLOGY MANAGEMENT, 2019, 16 (01)
  • [6] PEComa: what do we know so far?
    Hornick, JL
    Fletcher, CDM
    HISTOPATHOLOGY, 2006, 48 (01) : 75 - 82
  • [7] Refractory hypertension: what do we know so far?
    Elizabeth Silaid Muxfeldt
    Bernardo Chedier
    Journal of Human Hypertension, 2021, 35 : 181 - 183
  • [8] Tracheal papillomatosis: what do we know so far?
    Harris, Kassem
    Chalhoub, Michel
    CHRONIC RESPIRATORY DISEASE, 2011, 8 (04) : 233 - 235
  • [9] TAVI in nonagenarians, what do we know so far?
    Diez-Villanueva, Pablo
    Rivero, Fernando
    REC-INTERVENTIONAL CARDIOLOGY, 2021, 3 (04): : 245 - 246
  • [10] HIV and neoplasms: What do we know so far?
    de Souza, Thais Faria
    Sym, Yasmin Vianna
    Chehter, Ethel Zimberg
    EINSTEIN-SAO PAULO, 2023, 21 : eRW0231